Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWYX | ISIN: US19188J4094 | Ticker-Symbol: 8CC
Tradegate
24.04.25
16:49 Uhr
1,180 Euro
-0,080
-6,35 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COCRYSTAL PHARMA INC Chart 1 Jahr
5-Tage-Chart
COCRYSTAL PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2501,31024.04.
1,2401,36024.04.

Aktuelle News zur COCRYSTAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants39Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral...
► Artikel lesen
MiCocrystal Pharma, Inc. - 8-K, Current Report2
11.04.Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA (tapinarof) with Enhanced Therapeutic and Market Extension Prospects123Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as...
► Artikel lesen
08.04.Cocrystal Pharma, Inc. - 8-K, Current Report2
31.03.Cocrystal Pharma, Inc. - 10-K, Annual Report1
31.03.Cocrystal Pharma, Inc. - 8-K, Current Report2
31.03.Cocrystal Pharma GAAP EPS of -$1.721
COCRYSTAL Aktie jetzt für 0€ handeln
08.01.Cocrystal Pharma, Inc. - 8-K, Current Report5
31.12.24Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide1
31.12.24Cocrystal stock plunges 40% on influenza drug update2
31.12.24Cocrystal Pharma verlängert Studie aufgrund niedriger Grippeinfektionsrate9
31.12.24Cocrystal Pharma extends trial due to low flu infection rate1
31.12.24Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344176Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged...
► Artikel lesen
31.12.24Cocrystal Pharma, Inc. - 8-K, Current Report-
13.11.24Cocrystal Pharma, Inc. - 8-K, Current Report2
13.11.24Cocrystal Pharma GAAP EPS of -$0.49 beats by $0.082
13.11.24Cocrystal Pharma, Inc. - 10-Q, Quarterly Report-
31.10.24Cocrystal Pharma, Inc. - 8-K, Current Report1
15.08.24CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event428NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication...
► Artikel lesen
18.07.24Cocrystal Pharma, Inc.: Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor175BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") today reported favorable safety and tolerability results from the single-ascending...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1